Spiral Therapeutics, a clinical-stage biotechnology company developing therapies for inner ear disorders, announced the close of a $27 million Series B financing alongside a strategic research and development collaboration with Advanced Bionics.
The financing round was led by Gund Investment and included new strategic participation from Advanced Bionics and a major global pharmaceutical company, along with continued backing from existing investors including Ferring Ventures and Uni-Bio Science Group.
Proceeds from the financing will support the advancement of Spiral’s pipeline programs, including its lead candidate SPT-2101, as well as further development of its proprietary MICS drug delivery platform.
Concurrent with the funding, Spiral entered into a strategic collaboration with Advanced Bionics to explore sustained local drug delivery at the time of cochlear implantation. The partnership aims to combine Advanced Bionics’ expertise in cochlear implant technology with Spiral’s capabilities in targeted therapeutic delivery to improve patient outcomes.
Spiral’s lead program, SPT-2101, has demonstrated a statistically significant reduction in vertigo among patients with Ménière’s disease, and the company is preparing to initiate a registrational clinical trial. The company’s MICS platform is designed to enable minimally invasive, precise, and sustained delivery of therapeutics to the cochlea, supporting a broader pipeline of treatments for hearing loss and balance disorders.
Inner ear diseases represent a significant unmet medical need, with limited innovation historically. Spiral aims to address this gap through precision drug delivery technologies that enable new treatment approaches across multiple otologic conditions.
Headquartered in South San Francisco, Spiral Therapeutics is focused on advancing therapies that target the underlying biology of inner ear disorders and improving outcomes for patients with hearing and balance conditions.
KEY QUOTE:
“This financing is a major milestone for Spiral. It brings Advanced Bionics on as a strategic partner, welcomes Gund Investment as our Series B lead, and reinforces the continued support of our existing investors. Inner ear disorders are finally gaining the strategic attention long warranted by their prevalence and impact. Spiral stands out as one of a select few companies with a truly differentiated platform capable of enabling a robust pipeline of inner ear therapeutics.”
Hugo Peris, Founder and Chief Executive Officer, Spiral Therapeutics
